Menu
Search
|

Menu

Close
X

Erytech Pharma SA ERYP.OQ (NASDAQ Stock Exchange Global Select Market)

21.01 USD
-0.50 (-2.32%)
As of 2:29 AM IST
chart
Previous Close 21.51
Open 20.84
Volume 405
3m Avg Volume --
Today’s High 21.04
Today’s Low 20.84
52 Week High 30.48
52 Week Low 17.50
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 3 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Gil Beyen
Chairman of the Board and Chief Executive Officer, Since 2013
Salary: --
Bonus: --
Yann Godfrin
Deputy Chief Executive Officer, Director, Since 2016
Salary: €115,712.00
Bonus: €30,000.00
Jerome Bailly
Deputy Chief Executive Officer - Chief Pharmacist, Since 2011
Salary: €47,469.00
Bonus: €5,000.00
Eric Soyer
Chief Financial Officer, Chief Operating Officer, Since 2015
Salary: --
Bonus: --
Thomas Vigneron
Director of Quality Assurance and Information Systems, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Batiment Adenine 60 avenue Rocke
LYON     69008

Phone: +334.78744438
Site: erytech.com/

Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The Company's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death. The Company's subsidiary is Erytech Pharma, Inc in the USA which legal existence began in April 9, 2014.

SPONSORED STORIES